Live Breaking News & Updates on Myriad Genetics Precision Oncology Solutions

Myriad Genetics, Inc. (NASDAQ:MYGN) Q4 2023 Earnings Call Transcript February 27, 2024 Myriad Genetics, Inc. beats earnings expectations. Reported EPS is $0.04, expectations were $0.02. Myriad Genetics, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good day and welcome […] ....

Salt Lake City , United States , Sam Raha , Matt Scalo , Scott Leffler , Paul Diaz , Genetics Precision Oncology Solutions , Net Promoter Score , Myriad Collaborative , Myriad Genetics Precision Oncology Solutions , South San Francisco , Salt Lake , Precise Tumor , Precise Liquid Tests , Salt Lake City West , Chief Financial , Like Sam , Thanks Scott , Investor Relations , Best Skin , Most Breweries Per , Myriad Genetics , Paul Diaz , Fourth Quarter , Mark Verratti , Matt Scalo ,